Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

Share Price is delayed by 15 minutes
Get Live Data
222.00    -5.00 (-2.20%)
Bid:
222.00
Ask:
232.00
Spread: 10.00 (4.505%)
Market Cap: £117.21m
APTD Live PriceLast checked at - London Stock Exchange

Intraday Aptitude Share Chart

Interim Management Statement

13 May 2013 07:00

RNS Number : 4884E
Microgen PLC
13 May 2013
 



microgen

www.microgen.com

 

13 May 2013

 

INTERIM MANAGEMENT STATEMENT

 

 

Microgen plc ('Microgen' or 'Group') provides its Interim Management Statement covering the period from 1 January 2013 to the date of this announcement. Microgen released its final results for the year ending 31 December 2012 on 25 February 2013.

 

There have been no significant changes since 1 January 2013 in the financial position of Microgen and its balance sheet remains strong. The Group had net cash at 30 April 2013 of £32.3 million (31 December 2012 : £32.1 million) before payment of the dividend and special dividend totalling £6.1 million, scheduled for 28 May 2013.

 

The Board remains satisfied with the financial performance of the Group with benefit continuing to be received from its conservative operational approach and annual licencing model. The Financial Systems Division has commenced delivery of a significant 5Series project with a large global bank and continues to perform satisfactorily. The Microgen Aptitude Solutions Division ("MASD") has started implementation of a major new financial services project in North America based on both Microgen Aptitude and Accounting Hub. In addition, MASD has further strengthened its intellectual property portfolio with three new patents being granted by the US Patent Office since 1 January 2013 in respect of the Microgen Aptitude technology.

 

Strategic Review

 

The Microgen Group continues to be financially very robust with a strong balance sheet and consistent profitability/cash flow. Following payment of the dividend and special dividend, through the Board's pro-active shareholder realisation programme, Microgen will have returned to shareholders 100% of the market capitalisation as at 13 October 2008 via dividends, special dividends, tender offers and share buy-backs.

 

The Microgen Aptitude technology and related applications (e.g. Microgen Accounting Hub) continue to be affirmed as being market leading. Originally targeted at the financial services sector, which remains the core of the business, Microgen Aptitude has also established a strong reputation in the digital media sector and is now developing opportunities in both the telecom and healthcare sectors.

 

The Financial Systems Division operates in more established product categories with high recurring revenues. The core business which operates within the financial services sector has been stable for a number of years and continues to provide predictable cash flows. Furthermore, the investment in the development of the 5Series Trust & Fund administration product and an increasingly active wealth management market, have resulted in a number of new customer wins during the past year as well as upgrades from the previous 4Series product version.

 

Notwithstanding these strengths and the success of the shareholder realisation programme since October 2008, Microgen is constrained as a result of being a small, independent public company. As a provider of enterprise solutions in a risk-averse market environment, the size of the group can be an inhibitor given the very large enterprise software companies with which MASD typically competes. As a result, the Board has determined this to be an appropriate time to evaluate the Group's future strategy to maximise the potential of Microgen's market-leading technology and applications and has therefore decided to undertake a strategic review of the Group.

 

Given the financial strength of Microgen, continuing with the current strategy and structure remains a viable option. Nevertheless, the strategic review will be wide-ranging and may, or may not, result in the disposal of one or both of the operating divisions. Alternatively, the Board will also consider the merits of acquisition(s) to increase the scale of the Group, including acquisition(s) which may or may not provide operating synergies with the current operating divisions. Investec Bank Plc has been appointed to assist the Board in the strategic review.

 

The Board anticipates that this process will take several months. Further announcements will be made as appropriate.

 

 

 

 

 

 

 

Contacts

Martyn Ratcliffe, Chairman 020-7496-8100

David Sherriff, Chief Executive Officer

Philip Wood, Group Finance Director

 

James Melville-Ross, FTI Consulting 020-7831-3113

Lucy Delaney, FTI Consulting

 

Rowena Murray, Investec Bank Plc 020-7597 5970

Andrew Pinder, Investec Bank Plc

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSAMMATMBABBTJ
Date   Source Headline
15th Sep 20145:04 pmRNSHolding(s) in Company
1st Sep 20147:00 amRNSTotal Voting Rights
21st Jul 20147:00 amRNSInterim Results
14th Jul 20143:00 pmRNSNotice of Results
1st Jul 201412:11 pmRNSBlocklisting Interim Review
20th Jun 20148:10 amRNSDirector Declaration
17th Jun 20147:00 amRNSStatement regarding Elektron Technology plc
11th Jun 20149:34 amPRNForm 8 (OPD) Microgen plc
5th Jun 20142:20 pmRNSForm 8.3 - Microgen Plc
5th Jun 201412:13 pmRNSForm 8.3 - Microgen PLC
2nd Jun 20145:33 pmRNSForm 8 (OPD) Microgen plc
2nd Jun 201412:35 pmRNSForm 8.3 - [Microgen Plc]
2nd Jun 201410:50 amRNSTotal Voting Rights
30th May 201410:23 amBUSForm 8.3 - Microgen Plc
29th May 201410:08 amRNSRule 8.3 opening position disclosure
27th May 20142:39 pmPRNForm 8.3 - Microgen plc
27th May 20142:10 pmRNSStatement re Elektron Technology Plc
27th May 201411:44 amRNSForm 8.3 - Microgen Plc
23rd May 20145:22 pmRNSForm 8.3 - Microgen plc
23rd May 201410:22 amRNSForm 8.3 - Microgen Plc
21st May 20143:29 pmRNSForm 8.3 - [Microgen plc]
21st May 20143:04 pmRNSForm 8.3 - Microgen Plc
21st May 20142:13 pmRNSForm 8.3 - MICROGEN PLC
21st May 20141:10 pmRNSForm 8.3 - Microgen Plc
21st May 201411:48 amBUSForm 8.3 - Microgen Plc
21st May 201411:46 amRNSForm 8.3 - [MICROGEN PLC]
21st May 201411:21 amRNSForm 8.3 - MICROGEN ORD GBP0.05
21st May 20149:00 amRNSResponse to Microgen
20th May 201412:39 pmRNSFurther Statement Re Elektron Technology Plc
20th May 201410:20 amRNSStatement re Elektron Technology
2nd May 201410:48 amRNSDirector/PDMR Shareholding
1st May 201410:28 amRNSTotal Voting Rights
28th Apr 201411:28 amRNSResult of AGM
28th Apr 20147:00 amRNSInterim Management Statement
16th Apr 20145:24 pmRNSDirector Declaration
7th Apr 201411:04 amRNSBlocklisting Interim Review
11th Mar 201411:29 amRNSPosting of Annual Report & AGM
26th Feb 20147:00 amRNSPreliminary Results
20th Feb 201410:25 amRNSNotice of Results
10th Feb 20144:24 pmRNSHolding(s) in Company
14th Jan 201410:14 amRNSHolding(s) in Company
3rd Jan 20143:56 pmRNSBlocklisting Interim Review
18th Dec 20135:14 pmRNSDirector/PDMR Shareholding
5th Dec 201310:33 amRNSHolding(s) in Company
4th Dec 20135:52 pmRNSHolding(s) in Company
4th Dec 20134:23 pmRNSHolding(s) in Company
4th Dec 20134:20 pmRNSHolding(s) in Company
4th Dec 20134:19 pmRNSHolding(s) in Company
20th Nov 20137:00 amRNSResult of Tender Offer
18th Nov 201311:52 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.